Analyst Price Targets — OCGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 23, 2022 4:46 am | Uy Ear | Mizuho Securities | $5.00 | $2.34 | TheFly | Ocugen initiated with a Buy at Mizuho |
| August 15, 2022 11:41 am | — | H.C. Wainwright | $6.00 | $2.88 | Benzinga | HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $6 |
| June 18, 2022 2:00 pm | Jennifer Kim | Cantor Fitzgerald | $4.50 | $2.16 | Pulse 2.0 | Ocugen (OCGN) Stock Price: $4.50 Target And Overweight Rating |
| May 8, 2022 9:16 am | Daniil Gataulin | Chardan Capital | $3.50 | $2.16 | TheFly | Chardan keeps Neutral on Ocugen, lowers price target to $3.50 |
| April 25, 2022 2:12 am | Zegbeh Jallah | Roth Capital | $6.00 | $2.40 | Pulse 2.0 | Ocugen (OCGN) Stock: $6 Price Target And Buy Rating |
Latest News for OCGN
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to…
Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigmentosa and Stargardt disease next year and a third BLA for geographic atrophy in 2028.
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026.
MALVERN, Pa. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026.
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OCGN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.